Purpose: To develop a novel conditionally replicative adenovirus vector that targets telomerase-positive cancer cells.
INTRODUCTION
The most promising feature of the cancer gene therapy approach is the potential to exploit the genetic differences between normal and tumor cells so that effective killing of tumor cells is achieved without harming normal cells in the body. With this goal in mind, many efforts are under way to develop recombinant replication-competent virus vectors that can selectively replicate in tumor cells (1) (2) (3) . The eradication of tumor cells is achieved by virus-mediated cell lysis and subsequent infection and killing of neighboring cells. These recombinant viruses are termed "oncolytic" virus vectors (4 -7) .
One of the most popular approaches to achieve tumorspecific virus replication is the use of tumor-specific gene promoters to control the expression of essential virus genes. In this approach, the higher the specificity of the promoter, the more specific the engineered vector will be. One of the most universal tumor-specific genes identified thus far is the telomere reverse-transcriptase (TERT) gene. TERT is a ribonucleoprotein enzyme that is responsible for the maintenance of the normal length of telomeres (8) . In the overwhelming majority of somatic human cells, TERT is inactive (9) . Therefore, these cells have a finite life span, dictated by the length of their telomeres. Only a few normal cell types, which included the embryonic cells, germ cells, stem cells, and hematopoietic cells, have active TERT activity to enable them to divide constantly (10) . Cancer cells, on the other hand, have regained the ability to maintain a stable telomere length. This ability has been shown to be a result of the reactivation of the TERT transcription. Indeed, it was demonstrated that late stage tumors had high levels of telomerase activity. Several studies indicate that over 85% of all human tumors possess active TERT activities (11) .
The TERT promoter has been shown to mediate tumorspecific expression of a variety of cytotoxic genes. In this study, we report the successful use of the human (h)TERT (telomerase) promoter (12, 13) to control adenovirus vector replication. The newly engineered vectors showed strong tumor-specific replication in tissue-cultured cells. Effective lysis of the tumor cells was observed. In addition, strong intratumoral replication of the vectors was observed.
MATERIALS AND METHODS

Cell Lines
The 293 cells for virus production were obtained from the American Type Culture Collection (Manassas, VA). The other cell lines used include prostate cancer cell lines, LNCaP and Du145; breast cancer cell lines, MD-MB-231 and MCF-7; ovarian cancer cell lines, OVCR-3 and SKOV3; and colon cancer cell lines, HCT116 and HT29. These cell lines were obtained from the Cell Culture Facility of the Duke University Cancer Center and cultured in DMEM with supplementation of 10% fetal bovine serum. Two fibroblast cell strains from the Coriell Institute (Camden, NJ) were also used. They were also cultured in DMEM with 10% fetal bovine serum. In addition, prostate epithelial cells (PrECs) were used. They were purchased from Clonetics. Medium and supplements were obtained from the vendor to culture the cells. All of the tumor cell lines are known to possess telomerase activities (11) .
Engineering of Adenovirus Vectors
To engineer the telomerase-selective adenovirus, a 400-bp promoter for the hTERT gene was first cloned into the plasmid pTOPO-1 (Clontech, Palo Alto, CA) by PCR according to information published previously (12, 13) . The primers used for the PCR reaction were as follows: forward primer, 5Ј-TGGC-CCCTCCCTCGGGTTACCC-3Ј and reverse primer, 5Ј-CGCG-GGGGTGGCCGGGGCCAG-3Ј.
The DNA fragment that contains adenovirus E1 gene (kindly provided by Dr. Chinghai Kao of Indiana University) was subsequently ligated 3Ј to the cloned hTERT promoter. The native E1a promoter was deleted so that the hTERT promoter now controls the expression of the E1a gene. The E1b gene remained under the control of its native promoter. The hTERT-E1 gene expression cassette was then transferred into a plasmid p⌬E1sp1A (Microbix, Toronto, Canada), which contains the adenovirus left-side-inverted terminal repeat and virus-packaging signal. The dsRed2 gene, obtained from Clontech, was excised from the plasmid pDsRed2-N1 and transferred 5Ј to the hTERT-E1 and 3Ј to the packaging signal. The derived plasmid, p⌬E1sp1A-hTERT-E1-dsRed2 was then cotransfected into 293 cells with pBHG10 (Microbix, Ontario, Canada; Ref. 14). The ligation mixture was then transfected into 293 cells (with the help of liposome) for virus packaging. Active recombinant adenovirus appeared in 7-10 days in the form of "comet"-like structures (15) .
A similar procedure was used to derive the nonreplicative adenovirus Ad-dsRed2, which encodes the dsRed2 protein under the control of the cytomegalovirus promoter.
Production of Adenovirus in 293 Cells
A procedure similar to those described by Graham and Prevec (16) was followed to produce the adenovirus in large scale. Briefly, 293 cells were infected at a multiplicity of infection (MOI) of 5-10 using a total 1 ϫ 10 9 293 cells. After 3-4 days, the resultant viruses were purified by double CsCI banding. In general, about 3-10 ϫ 10 10 plaque-forming units (pfu) were yielded at the end of the amplification procedure by use of 293 cells cultured in 20 150-mm Petri dishes.
In Vitro Virus Infection Evaluation
To evaluate the capacity of the newly made adenovirus vectors to infect and replicate in various tumor and normal cells, the cells were infected at various MOIs. Virus infection and replication were then evaluated in the following ways:
DsRed2 Expression. DsRed2 expression was followed by observing the cells under a fluorescence microscope (Axioscope; Zeiss). Infected cells were also subjected to flow cytometry analysis by use of the FACScan apparatus from Becton Dickinson. It is part of the Duke University Cancer Center Core Facility.
Virus Plaque Assays. Virus plaque assays were carried by use of lysates from cells that have been infected with adenovirus vectors. The assays were carried out in 293 cells according to a published protocol (16) .
Evaluation of Oncolytic Activity of the Virus Vector
To evaluate the ability of AdTERT-E1a-dsRed2 to lyse tumor cells specifically, tumor and normal cells were infected with the virus vector at different MOI. At days 3 and 5 after viral infection, the number of live cells was quantified by use of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, which measures the activity of mitochondria enzymes in live cells. It was carried out by an established protocol (17). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was purchased from Sigma (St. Louis, MO). The catalogue number was M-5655.
In Vivo Evaluation of Virus Infection
To evaluate the ability of adenovirus vectors to infect and replicate in vivo, we established s.c. tumors by use of LNCaP prostate cancer cells (5 ϫ 10 6 cells in 50 l) and athymic Balb/C-derived nude mice (Charles River, Raleigh, NC). Virus vectors were injected into tumors when they reached sizes of 10 mm. About 5 ϫ 10 7 pfu of virus vectors (in 50 l of saline) were injected directly into the tumors by use of a 30-guage needle. At different time points after injection, the tumor-bearing animals were sacrificed and their tumors excised. Some tumors were sectioned and observed under a fluorescence microscope for dsRed2 expression although others were ground up in a tissue homogenizer. The homogenates were spun down, and the supernatants were evaluated for virus titer. Virus titer was determined using the approach of Graham and Prevec (16) . All animal procedures used in these experiments were approved by the Duke University Institutional Animal Use Committee.
RESULTS
Successful Construction of a Telomerase-Selective Adenovirus Vector Encoding Reporter Genes. To make a conditionally replicative adenovirus vector, we adopted a design as shown in Fig. 1 . A hTERT was used to control the expression of the adenovirus E1 gene. In addition, a reporter gene, dsRed2 (a red fluorescent protein from Discosoma) was engineered into the vector. A cytomegalovirus promoter controls it. The vector, Ad5TERT-E1a-dsRed2, was successfully made. We were able to produce the vector with high titers (3-10 ϫ 10 10 pfu/ml). Evaluation of Ad5TERT-E1a-dsRed2 in Various Normal and Malignant Cells. A series of experiments were conducted to evaluate whether the newly made virus could replicate HCT116 and HT29, were tested for their capacity to support active replication of AdTERT-E1a-dsRed2. In addition, a panel of normal cell strains was used. These included fibroblast strains GM8429, GM5658, and a normal human PrEC strain (PrEC).
An initial series of experiments were conducted to observe virus replication in cancer cells. Because our virus vector has a red fluorescent protein (dsRed2), virus infection and replication can be easily monitored by observation of dsRed2 expression under a fluorescent microscope.
Cells were infected with Ad5TERT-E1a-dsRed2 at a MOI of 0.05 pfu/cell, 0.1 pfu/cell, 0.5 pfu/cell, 1.0 pfu/cell, and 5 pfu/cell. As a control, they were also infected with Ad-dsRed2, which was a replication-deficient virus encoding the dsRed2 gene under the control of the cytomegalovirus promoter. The infected cells were then examined under a fluorescence microscope. A rhodamine filter was used. Active virus replication was seen in all tumor cell lines but was absent in all normal cell strains. The kinetics of virus replication was different among the tumor cell lines despite robust virus replication in all tumor lines. LNCaP, Du145, HCT116, and SKOV3 exhibited vary fast virus infection and replication kinetics whereas MCF-7 and MD-MB231 exhibited somewhat slower kinetics. The evidence for Du145 is shown in Fig. 2A , where the level of red fluorescent protein is reflective of the extent of virus replication. Among the normal fibroblast and epithelial cells, none showed the same level of virus replication as the tumor cells. Ad5TERT-E1a-dsRed showed roughly the same level of fluorescence as Ad-dsRed2 (data not shown), which indicated no significant virus replication in normal cells. Flow cytometry analysis was also conducted and the results confirmed the observations with fluorescence microscopy.
E1a gene expression in the infected cells would provide an independent verification of virus replication because it is an essential protein that was placed under the control of the hTERT promoter. Therefore, Western blot analysis was carried out to examine the level of E1a expression in Ad5TRE-E1a-dsRed2-infected normal and malignant cells. Fig. 2B shows the results. It was clear that detectable levels of E1 proteins were only produced in tumor cells, confirming the tumor-specific nature of Ad5TERT-E1a-DsRed2 replication.
A third assay that was used to confirm tumor-specific virus replication by use of a virus plaque-forming assay. This assay was aimed at quantifying the amount of active virus replication in infected normal and tumor cells. A nonreplicative AddsRed2, which encoded the dsRed2 gene under the control of a cytomegalovirus promoter, was used as a control. Seventy-two h after infection, the infected cells were harvested, and the amount of active viruses from the freeze-thawed cell lysates was evaluated by plaque-forming assays. The ratios of virus plaques in AdTERT-E1a-dsRed2-infected cells versus Ad-dsRed2-infected cells were then plotted. The results were shown in Fig.  2 . These results indicate that Ad5TERT-E1a-dsRed2 is at least three orders of magnitude more effective than Ad-dsRed2 in all of the tumor lines tested whereas the difference between the two is negligible in normal fibroblast cells and PrECs. These results essentially confirmed the observations made in the previous section.
A further assay was conducted to evaluate the tumorspecific oncolytic ability of Ad5TERT-E1a-dsRed2. After infection with Ad5TERT-E1a-dsRed2 at different MOI and incubation for different periods of time, the amount of viable cells were evaluated by staining with crystal violet or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Fig. 3 shows the results. It is clear that Ad5TERT-E1a-dsRed2 has very strong antitumor lytic capability and very weak activities in normal fibroblast or PrECs.
In Vivo Replication of AdTERT-E1a-dsRed2. To test the capacity of the newly synthesized vectors to replicate in vivo, AdTERT-E1a-dsRed2 was injected into xenograft LNCaP tumors established in nude mice. To do this, about 5 ϫ 10 injected with 5.0 ϫ 10 7 pfu of AdTERT-E1a-dsRed2 or the control nonreplicative Ad-dsRed2. Injections were carried out by use of 30-gauge needles to the center of tumors. Five days after injection, the tumors were excised and sectioned for examination. DsRed2 expression was examined. As shown in Fig.  4A , most of the tumor mass (over 90%) was infected with AdTERT-E1a-dsRed2. This was in comparison with Ͻ10% for Ad-dsRed2, a nonreplicative adenovirus that was used as a control. In addition, the level of dsRed2 expression was Ͼ100-fold higher (from quantitative fluorescence analysis) in Ad-TERT-E1a-dsRed2-infected tumors than in Ad-dsRed2-infected tumors. Virus replication in the tumors was also quantified by carrying out plaque-forming capability assays with excised tumor lysates 3 and 5 days after initial injection. Fig. 4B showed the results. It is clear that AdTERT-E1a-dsRed2 replicated significantly after injection whereas control (Ad-dsRed2) virus showed minimal replication. The differential is Ͼ10 3 -fold. This is an impressive result considering that it is done in vivo. Clearly, more experiments need to be carried out to verify the applicability of this differential in vivo.
An important remaining question is whether the current vectors will have antitumor efficacies when injected intratumorally. These experiments should be done in a variety of tumor lines to examine the relationship between the ability of the vector to replicate in vitro and the ability of the vectors to control tumor growth.
DISCUSSION
Specificity and efficiency of viral replication in target tumor cells are the two most important parameters used to evaluate the potential of any novel oncolytic vectors. In this study, we evaluated the merits of a novel oncolytic adenovirus strategy that can potentially be targeted to telomerase activities, which is present in over 90% of all tumor types. Our results, although limited in nature (more tumor lines need to be evaluated to test the ability of the virus to replicate in vivo), proved that this vector can indeed replicate efficiently in vitro and in vivo in tumor cells. More importantly, in normal cells where telomerase activities are absent, there was minimal virus replication. Therefore, our results demonstrated the great potential of the telomerase-targeted virus approach. The prototype oncolytic adenovirus vector is dl1520, or Onyx-015. It is an adenovirus vector that can selectively replicate in any cells that have lost the p53 tumor suppressor gene (1, 18) . This is based on the fact that adenovirus replication requires the inactivation of the p53 gene by the viral E1b protein. Therefore, Onyx-015, which has a mutation in the E1b gene that completely knocks out its p53 inactivation capability, can replicate in cells that have already lost p53 function but not in cells with wild-type p53. Because p53 is lost in over 50% of all tumors (70% for some tumors such as colon cancer), Onyx-015 can in theory be applied for the treatment of more than half of all tumors. To date, Onyx-015 has progressed into a phase III clinical trial (19) . Synergistic efficacy with chemotherapy has also been seen in patients in a phase I and a phase II trial (20) .
Another promising strategy involves the use of tumor or tissue-specific promoters to control the expression of genes required for viral replication. A typical example is the Calydon CN706, where the prostate-specific antigen gene promoter drives the expression of adenovirus E1a gene (21) . This virus was shown to have selective toxicity in prostate cancer cells. Even higher specificity was seen in another virus CN786, where the rat prostate-specific probasin promoter drives the expression of E1a although the prostate-specific antigen promoter drives the expression of E1b (22, 23) . Synergistic interaction with radiotherapy has also been reported (13) . Similar promoterdriven approaches have been reported by many other groups aimed at targeting different tumor types (24 -27) .
The TERT promoter as tested in our study demonstrated high specificity for tumor cells and high efficiency in mediating tumor cell-specific virus replication. These two characteristics make a telomerase-selective adenovirus vector very potent and promising as an oncolytic/gene delivery vector for cancer treatment. Compared with other types of conditionally replicative adenovirus vectors, such as Onyx-015, which can selectively replicate in p53-negative tumor cells (1, 18) , and Calydon CN706, which preferentially replicates in prostate-specific antigen-positive prostate cancer, the telomerase-based conditionally replicative adenovirus can, in theory, replicate in almost any tumor cells with telomerase activity. Because telomerase activity is by far the most common tumor marker (Ͼ90% in all tumor types), the telomerase-selective adenovirus vector can be adapted to almost all solid tumor types. Therefore, compared with other types of conditionally replicative adenovirus vectors, it has a much wider range for tumor therapy. For example, p53 defect is only detected in 65% of all tumors whereas the prostate-specific antigen expression is only specific for prostate cancer patients. In addition, telomerase activity is likely correlated with the malignancy of tumors (28, 29) . It is also known that the myc oncogene is a powerful regulator of telomerase activities (30, 31) . Therefore, a telomerase-selective gene therapy vector may have the potential of replicating in more malignant tumor types, such as those expressing higher levels of the myc oncogene, although this has to be proven experimentally.
Taken together, the telomerase-selective replicative adenovirus vector reported here may indeed warrant additional study as a novel treatment approach to achieve significant tumor cell killing with minimal normal tissue damage.
